We Are Patient Focused

Here at Ardelyx®, we are dedicated to improving the lives of patients by discovering, developing and commercializing first-in-class targeted therapies that advance patient care. Using our discovery model, Ardelyx scientists identified new biological mechanisms and pathways that enabled us to develop medicines designed to address significant unmet medical needs with the goal of improving outcomes for patients.

Ardelyx is publicly traded on the Nasdaq Global Market under the symbol ARDX

Logo Alt

The Ardelyx “A”

Since our founding, we have been focused on translating our deep understanding of biological mechanisms of ion transport into life-changing medicines. Our stylized “A” visually represents the promise of therapeutics when they interact with specific biological targets. While our logo has evolved over time, we have maintained our unique “A” to recognize our lasting commitment to scientific discovery for the benefit of patients.

Our Core Values


With integrity and determination, we make a difference for patients.


By challenging convention, we truly innovate.


Working tirelessly together, we are greater than the sum of our parts.


With respect, grace and humor, we are family.


Mike Raab

President &
Chief Executive Officer


Justin Renz

Chief Financial & Operations Officer

Elizabeth Grammer, Esq.

Chief Legal &
Administrative Officer

Laura Williams, MD MPH

Chief Medical Officer 

Robert Blanks, MS RAC

Chief Regulatory Affairs &
Quality Assurance Officer

David Rosenbaum, PhD

Chief Development Officer

Mike Kelliher

Executive Vice President
Corporate Development and Strategy

Charon Spencer

Charon Spencer

Chief Human Resources Officer

Board of Directors

David Mott

David Mott


Robert Bazemore

Robert Bazemore


William A. Bertrand, Jr., JD


Muna Bhanji R.Ph

Muna Bhanji, R.Ph


Onaiza Cadoret Manier

Onaiza Cadoret-Manier


Mike Raab

Mike Raab


Richard Rodgers

Richard Rodgers


Our Partners

Our global partners currently include Kyowa Kirin, Fosun Pharma, and Knight Therapeutics.

  • In November 2017, we executed a license agreement with Kyowa Kirin Co. Ltd., for the development and commercialization of tenapanor for cardiorenal diseases and conditions associated with them, including hyperphosphatemia, in Japan. Tenapanor, branded as PHOZEVEL®, is approved for hyperphosphatemia in Japan.
  • In December 2017, we executed a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for the development and commercialization of tenapanor for irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia related to chronic kidney disease in China.
  • In March 2018, we executed a license agreement with Knight Therapeutics, Inc. to commercialize tenapanor in Canada for the treatment of IBS-C and hyperphosphatemia. IBSRELA® (tenapanor) is currently available for the treatment of IBS-C in Canada.


At Ardelyx, we act on opportunities that reinforce our collective commitment to invest in our people and the communities we serve to build a more equitable and sustainable society. Ardelyx’s Environmental, Social and Governance (ESG) Report demonstrates our dedication and progress toward this important work.

Our Commitment to Compliance

At Ardelyx, we foster a culture of compliance and hold our employees, contractors and other representatives acting on our behalf to a high standard of business and professional conduct. Our core values—passionate, fearless, dedicated, inclusive—guide how we treat each other, our customers and our patients.